226 related articles for article (PubMed ID: 30223928)
1. Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Yoshida Y; Komori K; Aoki M; Sandou M; Takagi M; Uejima E
Pharmazie; 2018 Oct; 73(10):613-616. PubMed ID: 30223928
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Ohkura Y; Ueno M; Udagawa H
World J Surg Oncol; 2019 Jul; 17(1):125. PubMed ID: 31315622
[TBL] [Abstract][Full Text] [Related]
3. Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.
Ishikawa T; Yasuda T; Okayama T; Dohi O; Yoshida N; Kamada K; Uchiyama K; Takagi T; Konishi H; Shiozaki A; Fujiwara H; Konishi H; Naito Y; Teramukai S; Itoh Y
Cancer Sci; 2019 Dec; 110(12):3754-3760. PubMed ID: 31646714
[TBL] [Abstract][Full Text] [Related]
4. Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients.
Yoshimoto T; Oshima T; Fukada T; Imamura N; Nakanishi T; Ebisutani N; Morishita D; Mieno M; Nakai K; Sei H; Kitayama Y; Eda H; Okugawa T; Tomita T; Fukui H; Shinzaki S
Int J Clin Oncol; 2024 Feb; 29(2):142-148. PubMed ID: 38063978
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer.
Maeda O; Furune S; Kanda M; Miyata K; Shimizu D; Sugita S; Nishida K; Ando M; Kodera Y; Ando Y
Cancer Med; 2024 Jan; 13(2):e6974. PubMed ID: 38348961
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer.
Kurogochi T; Matsumoto A; Nyumura Y; Tanishima Y; Nakayoshi T; Okamoto T; Yano F; Eto K
Anticancer Res; 2023 May; 43(5):2293-2298. PubMed ID: 37097646
[TBL] [Abstract][Full Text] [Related]
7. [Impact of Primary Prophylaxis with Pegfilgrastim on Clinical Outcomes in Patients with Advanced Esophageal Cancer Receiving Chemotherapy with Docetaxel, Cisplatin ,and 5-FU].
Yasuda T; Ishikawa T; Ohta T; Yoshida J; Doi T; Dohi O; Okayama T; Yoshida N; Kamada K; Uchiyama K; Handa O; Takagi T; Konishi H; Shiozaki A; Fujiwara H; Naito Y; Itoh Y
Gan To Kagaku Ryoho; 2018 Dec; 45(12):1733-1736. PubMed ID: 30587730
[TBL] [Abstract][Full Text] [Related]
8. A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma.
Katada C; Sugawara M; Hara H; Fujii H; Nakajima TE; Ando T; Kojima T; Watanabe A; Sakamoto Y; Ishikawa H; Hosokawa A; Hamamoto Y; Muto M; Tahara M; Koizumi W
Jpn J Clin Oncol; 2021 Feb; 51(2):199-204. PubMed ID: 33147611
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of primary prophylaxis of febrile neutropenia with pegfilgrastim in docetaxel, cisplatin and 5-fluorouracil therapy for esophageal cancer.
Ichimura T; Nomura H; Shimizu H; Machida Y; Suzuki K
Pharmazie; 2021 Sep; 76(9):450-454. PubMed ID: 34481537
[No Abstract] [Full Text] [Related]
10. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.
Nomura H; Hatogai K; Maki Y; Mochizuki N; Tanaka M; Saito S; Daiko H; Kojima T; Kawasaki T
Support Care Cancer; 2020 Apr; 28(4):1849-1854. PubMed ID: 31342165
[TBL] [Abstract][Full Text] [Related]
11. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
Donkor KN; Selim JH; Waworuntu A; Lewis K
Ann Pharmacother; 2017 Oct; 51(10):840-847. PubMed ID: 28597691
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study.
Okamoto K; Ninomiya I; Saito H; Shimada M; Yamaguchi T; Terai S; Moriyama H; Kinoshita J; Nakamura K; Inaki N
Anticancer Res; 2022 May; 42(5):2783-2790. PubMed ID: 35489772
[TBL] [Abstract][Full Text] [Related]
14. Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study.
Maeda O; Fukaya M; Koike M; Miyata K; Kanda M; Nishida K; Ando M; Kodera Y; Ando Y
Asia Pac J Clin Oncol; 2022 Dec; 18(6):578-585. PubMed ID: 35043574
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
17. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
[TBL] [Abstract][Full Text] [Related]
18. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Holmes FA; Jones SE; O'Shaughnessy J; Vukelja S; George T; Savin M; Richards D; Glaspy J; Meza L; Cohen G; Dhami M; Budman DR; Hackett J; Brassard M; Yang BB; Liang BC
Ann Oncol; 2002 Jun; 13(6):903-9. PubMed ID: 12123336
[TBL] [Abstract][Full Text] [Related]
19. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
Eckstrom J; Bartels T; Abraham I; Patel H; Elquza E; Scott AJ; Malangone S; Hollings J; McBride A
Support Care Cancer; 2019 Mar; 27(3):873-878. PubMed ID: 30090991
[TBL] [Abstract][Full Text] [Related]
20. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
Cobb PW; Moon YW; Mezei K; Láng I; Bhat G; Chawla S; Hasal SJ; Schwartzberg LS
Cancer Med; 2020 Sep; 9(17):6234-6243. PubMed ID: 32687266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
